Pharmacovigilance
Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Fenatnyl‐Janssen ® - Fentanyl | 2013-07-14 | Fenatnyl‐Janssen Introduction of New Warning ‐ Serontonin syndrome may occur under co‐administration with serotonergic drugs.
|
|
| DUROGESIC® -Fentanyl | 2013-07-14 | Introduction of New Warning-Serontonin syndrome may occur under co-administration with serotonergic drugs.
|
|
| TASIGNA® - Nilotinib | 2013-07-14 | Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®. |
|
| VOTRIENT® - Pazopanib | 2013-07-14 | Important change to frequency of Serum liver test monitoring for hepatotoxicity.
|
|
| Cilest® - Ethinylestradiol, Norgestimate | 2013-07-08 | The reason for the recall is that dissolution testing of norgestimate.
|
|
| TYKERB® - Lapatinib | 2013-06-26 | Comparative data have shown that Lapatinib based regimens are less effective than trastuzumab based regimens in certain settings.
|
|
| Plavix® - Clopidogrel | 2013-06-19 | Regarding Bleeding Risk with Plavix in Atrial Fibrillation Patients.
|
|
| Curacne® - Isotretinoin | 2013-06-10 | Pregnancy Prevention Program
|
|
| ROACCUTANE®- Isotretinoin | 2013-06-09 | Pregnancy Prevention Program
|
|
| Tysabri® - Connect | 2013-05-29 | Risk of progressive multifocal leukoencephalopathy PML |